---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-005635"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:25:15.791716+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro faces Nasdaq delisting over MVLS; sells $780K Series B convertible to affiliate

## Summary
- Nasdaq notified ALZN it fails MVLS rule; delisting scheduled for April 4 unless appeal stays it.
- Company will appeal to Hearings Panel by April 2; Common Stock continues trading pending decision.
- Sold Series B convertible preferred stock and warrants for $780K to Ault Lending (affiliate); aggregate purchases now $2M of $6M available.
- Unregistered sale under Section 4(a)(2) exemption.

## SEC filing metadata
- accession: 0001214659-24-005635
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/0001214659-24-005635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/p3292438k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-005635
- JSON: https://secwatch.observer/filing/0001214659-24-005635.json
- Plain text: https://secwatch.observer/filing/0001214659-24-005635.txt

## Key facts
- Listing & Compliance Notices
  Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: iled with the Securities and Exchange Commission (the “ SEC ”), which will remove the Common Stock from listing and registration on Nasdaq. The Company will request an appeal of the Staff’s determination to a Hearings Panel (the “ Panel ”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, which is required to be submitted electronically no later than April 2, 2024. The hearing request will stay the suspension of the Common Stock and the filing of the Form 25-NSE pending the Panel’s decision, and the Common Stock will continue to trade on the Nasdaq Capital Market un
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/0001214659-24-005635-index.htm
- Material Agreements
  Alzamend Neuro, Inc. entered into Agreement with Ault Lending, LLC valued at purchase price of $2.0 million (effective 2024-01-31).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Ault Lending, LLC
  - Value: purchase price of $2.0 million
  - Effective: 2024-01-31
  source text: On March 26, 2024, Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), pursuant to the Securities Purchase Agreement (the “ Agreement ”) entered into with Ault Lending, LLC, a California limited liability company (the “ Purchaser ”) on January 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924005635/0001214659-24-005635-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.